SD Biosensor lists TB test globally and reports growth for SD Biosensor stock

Published on 10/19/2026 at 03:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SD Biosensor's STANDARD M10 reached the Global Fund list on September 30, 2026. SD Biosensor stock had Q2 revenue of KRW 186.48 billion.

TB diagnostic expansion

SD Biosensor listed its STANDARD M10 MTB-RIF/INH test on the Global Fund procurement list on September 30, 2026.
Second-quarter 2026 revenue rose 12.00 percent year over year to KRW 186.48 billion.
SD Biosensor's market capitalization stood at KRW 818.2 billion on October 19, 2026.

SD Biosensor, KR7137310009, Illustration mit AI erstellt.

SD Biosensor (ISIN KR7137310009) reported second-quarter 2026 revenue of KRW 186.48 billion, up 12.00 percent from the year-earlier period, while its STANDARD M10 MTB-RIF/INH test was listed on the Global Fund procurement list on September 30, 2026. The development gives the diagnostics maker a concrete route into drug-resistant tuberculosis testing.

Global Fund listing broadens reach

According to SD Biosensor, the STANDARD M10 MTB-RIF/INH product targets the global drug-resistant tuberculosis diagnostics market. The listing matters because procurement access can connect a test platform with public-health purchasing channels across multiple markets.

The company also presented its products at medical conferences in Korea during September 2026, according to the same company news page. Its portfolio includes rapid tests, fluorescence immunodiagnostic systems, enzyme immunoassays and point-of-care molecular diagnostics.

What do the second-quarter figures show?

The revenue increase was paired with a KRW 7.30 billion operating loss and KRW 16.30 billion of net income in the second quarter of 2026, according to ATS View. The contrast leaves operating profitability as the central test for whether new procurement channels can translate into durable earnings.

SD Biosensor held KRW 230.22 billion in cash and cash equivalents at June 30, 2026, while second-quarter operating cash flow was KRW 1.55 billion. The financial profile combines a stronger sales line with a still-negative operating result.

Next reporting date is November 16

Investing.com lists November 16, 2026, as the next earnings date. That report should show whether the second-quarter revenue growth and the procurement-list expansion are being reflected in operating performance.

Market value and Korean listing

SD Biosensor trades on the Korea Exchange KOSPI market under ticker 137310. Its market capitalization stood at KRW 818.2 billion on October 19, 2026, and the 52-week range was KRW 5,800.00 to KRW 10,190.00. On the KRX, the stock was last at KRW 6,840 on October 19, 2026 at 9:50 a.m. KST.